Literature DB >> 10738212

Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study.

T Tono1, Y Hasuike, H Ohzato, Y Takatsuka, N Kikkawa.   

Abstract

BACKGROUND: Greater than 50% of patients who undergo curative resection of liver metastases from colorectal carcinoma develop recurrent disease in the residual liver. Although several studies have attempted to use hepatic arterial infusion (HAI) chemotherapy to prevent recurrence, to the authors' knowledge the efficacy of the treatment has not yet been determined.
METHODS: Nineteen patients who underwent curative hepatectomy for metastatic colorectal carcinoma randomly were assigned into the HAI group (nine patients) or the control group (ten patients). Patients in the HAI group received continuous intraarterial infusion of 5-fluorouracil (5-FU) (500 mg/day) for 4 days followed by a 3-day rest. The treatment was continued for 6 weeks.
RESULTS: The median follow-up period was 62.2 months. The recurrence was confirmed in three patients in the HAI group and in eight patients in the control group. Of these, recurrence in the remnant liver was observed in one patient and in six patients, respectively. The median disease free interval after hepatectomy was 62.6 months in the HAI group and 13.8 months in the control group. The 1-year, 2-year, and 3-year disease free survival rates were 77.8%, 77.8%, and 66.7%, respectively, in the HAI group and 50.0%, 30.0%, and 20.0%, respectively, in the control group. Significant prolongation of disease free survival was observed in the HAI group (P = 0.045). No patients in the HAI group reported any adverse effect of >/= Grade 2 (according to the National Cancer Institute Common Toxicity Criteria). Two patients in the HAI group and five patients in the control group were dead of disease at the time of last follow-up. The 1-year, 3-year, and 5-year cumulative survival rates for the HAI group were 88.9%, 77.8%, and 77.8%, respectively, whereas those of the control group were 100.0%, 50.0%, and 50.0%, respectively (P = 0.2686).
CONCLUSIONS: This randomized study revealed that short term HAI of 5-FU after curative resection of colorectal hepatic metastases is effective in preventing the recurrence of disease without any serious complications. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10738212

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

Review 1.  Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update.

Authors:  Thomas J Vogl; Stephan Zangos; Katrin Eichler; Danny Yakoub; Mohamed Nabil
Journal:  Eur Radiol       Date:  2006-08-30       Impact factor: 5.315

2.  Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials.

Authors:  Thomas E Clancy; Elijah Dixon; Roy Perlis; Francis R Sutherland; Michael J Zinner
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

3.  5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma.

Authors:  Jin-Fang Zheng; Hai-Dong Wang
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

Review 4.  A systematic review and meta-analysis to reappraise the role of adjuvant hepatic arterial infusion for colorectal cancer liver metastases.

Authors:  Wei Liu; Qing-Kun Song; Bao-Cai Xing
Journal:  Int J Colorectal Dis       Date:  2015-05-27       Impact factor: 2.571

5.  Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.

Authors:  John S Bolton; Michael J O'Connell; Michelle R Mahoney; Gist H Farr; Tom R Fitch; William J Maples; David M Nagorney; Joseph Rubin; Jyotsna Fuloria; Preston D Steen; Steven R Alberts
Journal:  Clin Colorectal Cancer       Date:  2011-05-13       Impact factor: 4.481

Review 6.  Current preventive treatment for recurrence after curative hepatectomy for liver metastases of colorectal carcinoma: a literature review of randomized control trials.

Authors:  Peng Wang; Zhen Chen; Wen-Xia Huang; Lu-Ming Liu
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

Review 7.  Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer.

Authors:  Sotaro Sadahiro; Toshiyuki Suzuki; Akira Tanaka; Kazutake Okada; Hiroko Kamata; Jun Koisumi
Journal:  Surg Today       Date:  2012-11-10       Impact factor: 2.549

8.  Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).

Authors:  Jing Jin; Min Huang; Huai-Ling Wei; Geng-Tao Liu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

Review 9.  Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials.

Authors:  Martina Wieser; Stefan Sauerland; Dirk Arnold; Wolff Schmiegel; Anke Reinacher-Schick
Journal:  BMC Cancer       Date:  2010-06-21       Impact factor: 4.430

Review 10.  Complications of hepatic artery infusion: a review of 4580 reported cases.

Authors:  K T Barnett; M P Malafa
Journal:  Int J Gastrointest Cancer       Date:  2001
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.